What changed for Transverse Myelitis
A plain English summary of what recently moved in the public data Voxsanity tracks for Transverse Myelitis. Updated from government registries. Not medical advice.
How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.
Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.
- Trials recruiting worldwide 48 to 49 (+1)
- Trials on record 182 to 183 (+1)
Newly subsidised on the PBS
No PBS-reviewed medicines are tracked for Transverse Myelitis yet, so new PBS listings cannot be reported for it. This is a gap in what Voxsanity has mapped, not a statement that no medicines are subsidised — check the PBS directly.
Past updates
Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.
Recent trend
Weekly, most recent weeks (fills out to a monthly trend as history grows).
Recent trial results
Trials tracked for Transverse Myelitis that have reported results to a public registry.
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
-
NCT04614454 · results posted 30 April 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04614454) enrolled 46 people in total — 23 in the experimental arm and 23 in a sham (inactive/comparison) arm. The trial was measuring changes in pain levels and quality of life over four weeks, comparing those who received the experimental treatment to those who received a sham version of it. Of those who started, 19 people in the experimental arm and 21 in the sham arm completed the trial. The reported data shows that the main thing being measured was change in pain, using a numbered scale from 0 (no pain) to 10 (worst...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05269667 · results posted 22 January 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05269667) enrolled 4 participants in a single group, described as people with a condition called NMOSD (a rare disease affecting the nerves of the eyes and spinal cord) who had not responded well enough to a previous treatment called rituximab. The trial was measuring how participants responded to a medicine called satralizumab, focusing on whether they experienced relapses — defined as new or worsening neurological symptoms linked to their condition. Notably, none of the 4 participants completed the study; all 4 were list...
-
NCT04660539 · results posted 27 December 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04660539) was an extension study involving 166 people who had previously taken part in earlier trials of a medicine called satralizumab, used in the treatment of a rare neurological condition called neuromyelitis optica spectrum disorder (NMOSD). Of the 166 who started, 106 completed the study and 60 did not finish. The study was primarily measuring the number of participants who experienced unwanted medical events (called adverse events) and more serious unwanted medical events (serious adverse events) over the course of...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04155424 · results posted 25 September 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04155424) enrolled 5 participants, all of whom received the study drug eculizumab. All 5 participants took part in both the induction and maintenance phases of the treatment period. Notably, none of the 5 participants were recorded as having "completed" the study — all 5 were listed under "not completed," though the reasons for this are not detailed in the reported data. The trial was primarily measuring how often relapses (flare-ups of the condition) occurred during the study compared to the two years before it began, as...
-
NCT04201262 · results posted 9 August 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT04201262) enrolled 105 adults in total — 58 received a medicine called ravulizumab and 47 received a placebo (an inactive dummy treatment). The trial was measuring whether ravulizumab could reduce relapses (sudden worsening episodes) in people with a rare nerve condition called NMOSD (neuromyelitis optica spectrum disorder). The main treatment period was followed by a longer-term extension phase, which only the ravulizumab group continued into. The reported data shows that, during the main treatment period, zero out of 58...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02865018 · results posted 7 June 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT02865018) involved 16 people who were given cetirizine (an antihistamine medication). One participant did not complete the study, leaving 15 who finished. The trial was measuring the rate of relapses (episodes of worsening symptoms) in people with multiple sclerosis, before and during treatment with cetirizine. It also measured sleepiness, disability levels, and a blood marker related to a type of immune cell called an eosinophil. The reported data shows that the annualised relapse rate — that is, the estimated number of...
-
NCT02003144 · results posted 23 August 2022
According to the results reported on ClinicalTrials.gov, this trial (NCT02003144) enrolled 119 participants in total — 41 in the "Placebo then Eculizumab" group and 78 in the "Eculizumab throughout" group. The trial was measuring a range of things, including how many participants experienced unwanted medical events (called adverse events), any thoughts or behaviours related to suicide (using a standardised questionnaire), and how often participants had relapses — that is, new or worsening neurological symptoms lasting more than 24 hours. The trial had two phases: a blinded phase (where some pa...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02073279 · results posted 31 December 2020
According to the results reported on ClinicalTrials.gov, this trial studied a medicine called satralizumab in people with neuromyelitis optica (NMO) or neuromyelitis optica spectrum disorder (NMOSD) — conditions where the immune system attacks the nerves in the eyes and spine, causing relapses (sudden episodes of new or worsening symptoms). The trial had two stages: a blinded phase where neither doctors nor participants knew who received satralizumab or a dummy treatment (placebo), followed by an open-label phase where everyone received satralizumab. In the blinded phase, 32 people started in...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03002038 · results posted 30 September 2020
According to the results reported on ClinicalTrials.gov, this trial involved 86 people in total — 46 were given a medicine called azathioprine and 40 were given a medicine called rituximab. The trial was looking at people with a relapsing condition (most likely multiple sclerosis, based on the measures used) and compared how the two medicines performed over 12 months. By the end of the study, 35 people in the azathioprine group and 33 in the rituximab group had completed the trial. The primary thing being measured was how often participants experienced relapses (flare-ups of their condition)...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03452176 · results posted 17 April 2020
According to the results reported on ClinicalTrials.gov, this trial involved 22 people in total — 11 in the "Scrambler" group (who received the active treatment) and 11 in the "Sham-Control" group (who received a inactive/dummy version of the treatment). The trial was not designed to prove whether the treatment works; instead, it was a small study focused on two practical questions: whether participants would want to keep using the treatment if it were available (called "acceptability"), and whether people could realistically stick to the 10 scheduled treatment visits (called "feasibility"). P...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT00787722 · results posted 28 February 2020
According to the results reported on ClinicalTrials.gov, this trial enrolled 13 participants, all of whom underwent a procedure called haematopoietic stem cell transplantation (HSCT) — a process where a person's own blood-forming stem cells are used to try to "reset" the immune system. Twelve of the 13 participants completed the study. The trial was looking at a condition called neuromyelitis optica (NMO), a rare disease that attacks the nervous system. The researchers tracked survival, quality of life, disability levels, walking ability, immune-related medications, disease relapses, and level...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT00879658 · results posted 13 January 2020
According to the results reported on ClinicalTrials.gov, this trial tested a drug called BAF312 (also known as siponimod) in people with multiple sclerosis. The study was run in two periods, with participants receiving different doses of BAF312 — ranging from 0.25 mg up to 10 mg — or a placebo (a dummy treatment with no active ingredient). Across both periods, a total of 297 people started the study, spread across seven treatment groups. The trial was mainly measuring how BAF312 affected brain lesions (areas of damage) visible on MRI scans, and whether there was a pattern where higher doses pr...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02200770 · results posted 26 December 2019
According to the results reported on ClinicalTrials.gov, this trial (NCT02200770) looked at a condition called Neuromyelitis Optica Spectrum Disorder (NMOSD), a rare disease that can cause episodes of worsening symptoms affecting vision, movement, and other functions. A total of 231 people took part in the main controlled phase — 56 received a placebo (an inactive treatment) followed later by the study drug inebilizumab, while 175 received inebilizumab from the start. The trial was primarily measuring how long it took before participants experienced a confirmed NMOSD attack, and also tracked a...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01892345 · results posted 26 June 2019
According to the results reported on ClinicalTrials.gov, this trial (NCT01892345) enrolled 143 people in total — 96 in the eculizumab group and 47 in the placebo group. The trial was measuring outcomes in people with a neurological condition, with the main question being how many participants experienced a confirmed relapse (a new or worsening bout of neurological symptoms lasting more than 24 hours, verified by a doctor and reviewed by an independent committee) during the study period. Secondary measurements included how often relapses occurred over time, changes in disability scores, walking...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02276963 · results posted 6 June 2019
According to the results reported on ClinicalTrials.gov, this trial (NCT02276963) enrolled 6 participants, all of whom received a combination of ublituximab (a type of infused medicine) and glucocorticoids (a type of steroid medicine). The trial was measuring changes in neurological disability using a tool called the Expanded Disability Status Scale, or EDSS — a scoring system that runs from 0 (no disability) to 10 (deceased), where a higher number reflects greater disability. Of the 6 people who started the trial, 3 completed it and 3 did not complete it; the reasons for not completing were n...
-
NCT02166346 · results posted 17 April 2018
According to the results reported on ClinicalTrials.gov, this was a crossover trial — meaning participants took both the study drug (dalfampridine) and a dummy pill (placebo) at different points in time. A total of 24 people were enrolled at the start, but 8 did not continue past the initial screening and randomisation stage, leaving 16 people who entered the treatment phases. The trial was measuring walking speed and muscle strength in people taking dalfampridine compared to placebo. The reported data shows that for the primary measure — walking speed over a 25-foot walk — individual partici...
-
NCT00179478 · results posted 6 September 2017
According to the results reported on ClinicalTrials.gov, this trial involved 155 people who had experienced a first episode of visual or neurological symptoms that could be an early sign of multiple sclerosis (MS). Participants were split into two groups: 81 people who started treatment straight away (the "Immediate Treatment Group") and 74 who had their treatment delayed (the "Delayed Treatment Group"). The trial followed participants for up to 10 years and was measuring whether starting treatment earlier made a difference to the chances of going on to develop a confirmed MS diagnosis, as wel...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT00904826 · results posted 4 November 2013
According to the results reported on ClinicalTrials.gov, this trial enrolled 14 participants, all of whom completed the study — none dropped out. The trial was looking at a medicine called eculizumab and its potential role in neuromyelitis optica (NMO), a rare condition that can cause episodes of inflammation affecting the eyes and spinal cord. The main thing the researchers were measuring was how many NMO "attacks" (sudden flare-ups of the condition) participants experienced per year. The reported data shows that before joining the trial, participants had a median (middle value in the group)...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
What is coming
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, a moderate amount of public research funding has been directed toward Transverse Myelitis, which suggests the condition has attracted meaningful scientific attention at a national level in the United States. However, the direction of that funding has been falling year on year, which may indicate that research interest or prioritisation is shifting away from this cond...
See the full Transverse Myelitis page
Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.